Alaa Eldeen Yassin | nanomedicine | Best Researcher Award

Prof. Alaa Eldeen Yassin | nanomedicine | Best Researcher Award 

Professor of Pharmaceutics, at King Saud bin Abdulaziz University for Health Sciences, Saudi Arabia.

Professor Alaa Eldeen Bakry Yassin is a distinguished Professor of Pharmaceutics at the College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences (KSAU-HS). With a career dedicated to advancing pharmaceutical sciences, he plays a pivotal role in shaping the Pharm D curriculum, coordinating core courses in pharmaceutics and pharmacokinetics. He has also led initiatives in nanomedicine and pharmaceutics, spearheading the proposal for a Master’s program. Through his research leadership, he has established a cutting-edge nano-drug delivery research line, successfully mentoring over 30 students and colleagues, and securing substantial research funding. Professor Yassin is a prolific contributor to the scientific community, with over 40 publications and conference presentations enhancing knowledge in drug delivery and nanotechnology.

Profile

Scopus

Google Scholar

ORCID 

Education

🎓 Professor Yassin has a strong academic foundation that underpins his research excellence in pharmaceutics. He earned his degrees in pharmaceutical sciences, focusing on innovative drug delivery methods and nanotechnology. His advanced training allowed him to pioneer controlled-release and nano-particulate systems, and his educational achievements have enabled him to contribute substantially to academia, mentoring numerous students and junior faculty. By developing expertise in advanced pharmaceutics and nanomedicine, Professor Yassin has established himself as a leader in drug formulation and delivery research, dedicated to enhancing patient treatment outcomes through innovative therapeutic methods.

Experience

🧑‍🏫 With over a decade of experience in pharmaceutics, Professor Yassin has demonstrated exceptional expertise in academia and research. At KSAU-HS, he coordinates core pharmaceutics courses, guiding students through critical aspects of pharmacokinetics and advanced drug delivery systems. His extensive involvement includes chairing research committees and leading nano-drug delivery projects. Over the past five years, he has supervised over 30 students and faculty members, and his guidance has led to significant advancements in nanomedicine. His commitment to education and research is further underscored by his role in securing grants for high-impact research in innovative drug delivery methods.

Research Interests

🔬 Professor Yassin’s research focuses on pioneering new drug delivery systems, especially targeting cancer nanomedicine. His primary interests include nano-particulate systems like solid lipid nanoparticles, polymeric nanoparticles, and hybrid nano-systems, which enhance the bioavailability and efficacy of poorly absorbed drugs. He explores diverse controlled-release and site-specific delivery mechanisms, including colon-targeted and transdermal systems, aiming to improve patient outcomes through innovative nanotechnology applications. His work in controlled release dosage forms and cancer-targeting therapies places him at the forefront of pharmaceutics, where he continuously contributes to transforming therapeutic efficacy in clinical settings.

Awards

🏆 Professor Yassin’s contributions have been widely recognized, earning him prestigious awards. In 2019, he received the Ministry of National Guard-Health Affairs Basic Research Track’s Researcher Award and the KSAU-HS President Award for Best Faculty. His groundbreaking research also garnered him the Kayyali Prize for Scientific Research by the Saudi Pharmaceutical Society in 2014. These accolades reflect his dedication to advancing pharmaceutical sciences, his role as an influential educator, and his ongoing commitment to innovative research, positioning him as a leader in pharmaceutics and nanomedicine.

Top Noted Publications

📚 Professor Yassin has authored numerous impactful publications in indexed journals, contributing to advancements in drug delivery and nanotechnology. Here are selected publications with links and citation counts:

  • Yassin, A.E., Fayed, B., & Tawfik, T.A. (2013). Enhancing The Stability of Recombinant Human Erythropoietin. LAP Lambert Academic Publishing. ISBN-10: 3659348554, ISBN-13: 978-3659348556.
  • Design and optimization of nanocapsule oral delivery system(s) for poorly
    absorbed drug, Research center of Pharmacy, KSU No. C.P.R.C. with total budget
    35,000 SR.
  • The development of new drug delivery system for diagnosis and treatment of
    colon cancer, King Abdulaziz city for science and technology No. AT-25-23 with
    total budget 880,286 SR.
  • Modified geometry three-layer tablet as a platform class II drugs zero order
    release system. King Abdullah International Medical Research Centre (KAIMRC),
    SP14-071 with total budget 29,567 SR.

Conclusion

Dr. Alaa Eldeen Bakry Yassin’s accomplishments in pharmaceutics and his pioneering work in nanomedicine make him a compelling candidate for the Best Researcher Award. His extensive funding record, significant publication output, and contributions to student and faculty mentorship underscore his influence in pharmaceutical sciences. With a continued focus on expanding his international partnerships and pursuing additional industry collaborations, Dr. Yassin is well-positioned to lead impactful advancements in nano-drug delivery. He is a deserving candidate who aligns well with the criteria for this award.

 

Aboubakr H. Abdelmonsef | Drug Design | Best Researcher Award

Assoc. Prof. Dr. Aboubakr H. Abdelmonsef | Drug Design | Best Researcher Award

Associate Professor, at South Valley University- Faculty of Science, Egypt. 

Dr. Aboubakr Haredi Abdelmonsef is an Associate Professor specializing in Organic Chemistry, Bioinformatics, and Drug Design at South Valley University, Egypt. With a strong foundation in organic chemistry and computational biology, he has established himself as a prominent figure in medicinal chemistry. Dr. Abdelmonsef’s research focuses on synthesizing biologically active molecules, analyzing their structural properties, and developing computational models to facilitate drug discovery. Over the years, he has contributed to various research projects, published extensively in peer-reviewed journals, and presented at numerous international conferences. His dedication to advancing science is reflected in his impressive publication record and the impact of his work, as highlighted by his h-index of 17 on Scopus. Dr. Abdelmonsef is known for his interdisciplinary approach, integrating organic synthesis and bioinformatics to address pressing health challenges.

Profile

Scopus

Google Scholar

ORCID

Education 🎓

Dr. Abdelmonsef received his Ph.D. in Chemistry from Osmania University, India, where he specialized in organic chemistry and computational studies for drug discovery. He also attended Jacobs University Bremen, Germany, as a visiting Ph.D. student, where he enhanced his expertise in computational chemistry. His doctoral work, which combined experimental synthesis with computational approaches, laid the foundation for his later contributions in bioinformatics and drug design. Dr. Abdelmonsef began his academic journey with a solid background in chemistry, progressively expanding his expertise into bioinformatics. This diverse educational background has enabled him to bridge gaps between organic synthesis and computational biology, making him a valuable asset in interdisciplinary research within his field.

Experience 💼

Dr. Abdelmonsef is an Associate Professor at South Valley University’s Chemistry Department, where he has taught and conducted research since 2006. His academic journey includes roles as an Assistant Professor, Assistant Lecturer, and Teaching Assistant. He also gained international experience as a visiting Ph.D. student at Jacobs University in Germany, enhancing his skills in computational modeling. His research career began with roles focusing on organic synthesis, gradually evolving to include bioinformatics and computational drug design. Throughout his career, he has supervised students, led workshops, and published extensively, making significant contributions to medicinal chemistry and bioinformatics. His multifaceted experience reflects his dedication to both academia and practical applications in chemical research.

Research Interests 🔬

Dr. Abdelmonsef’s research interests lie at the intersection of organic chemistry, bioinformatics, and drug design. He is particularly focused on developing and synthesizing novel bioactive molecules and using computational tools to understand their interactions with biological targets. His work includes molecular docking, QSAR studies, and in silico screening, aiming to accelerate drug discovery and address challenges in antimicrobial and anticancer therapy. Additionally, he explores the structural properties of heterocyclic compounds and their potential as therapeutic agents. Dr. Abdelmonsef’s interdisciplinary approach combines traditional synthesis with advanced computational techniques, allowing him to contribute valuable insights into bioactive molecule design and the potential development of new pharmaceuticals.

Awards 🏆

Dr. Abdelmonsef has received several accolades for his contributions to chemistry, including recognition for his research on bioactive molecules and computational drug design. His work has garnered both national and international attention, emphasizing his commitment to advancing medicinal chemistry. His achievements include awards from prominent conferences and academic institutions, underscoring his reputation in the scientific community. Dr. Abdelmonsef’s h-index of 17 is a testament to the impact of his research, and his contributions continue to influence the field of organic and medicinal chemistry. His recognition highlights his dedication to innovation in chemical research and his commitment to advancing drug discovery.

Publications 📚

Dr. Abdelmonsef has an extensive list of publications, contributing to the fields of organic chemistry and drug design. His works include:

  • Synthesis, spectroscopic characterization, antimicrobial activity, and computational studies of five and/or six heterocyclic nitrogen rings linked to thienopyrazole moiety” – Journal of Molecular Structure (2024)
    This study explores the synthesis and structural analysis of heterocyclic compounds containing nitrogen rings connected to a thienopyrazole core. The research emphasizes antimicrobial activity assessment against various bacterial strains, with computational studies supporting the understanding of the binding interactions of these compounds with microbial proteins. The article has been widely cited for its methodology and results in medicinal chemistry research.
  • “Novel Pyrazole-Linked Pyran Hybrids: Synthesis, Anti-inflammatory Evaluation, Molecular Docking Studies” – Egyptian Journal of Chemistry (2024)
    This paper reports on the synthesis of pyrazole-pyran hybrid compounds, which were tested for anti-inflammatory properties. Molecular docking studies are also included, showing potential receptor interactions that may contribute to the anti-inflammatory effects observed. This research has been referenced broadly for its innovative approach to hybrid compound synthesis and its potential implications in anti-inflammatory drug development.
  • “New 1,3-Diphenyl-1H-pyrazol-5-ols as Anti-Methicillin Resistant Staphylococcus aureus Agents” – Heliyon (2024)
    Focused on combating Methicillin-resistant Staphylococcus aureus (MRSA), this study presents novel pyrazol-5-ols with potential antibacterial activity. The research is significant due to the pressing need for effective MRSA treatments, and the synthesized compounds exhibited promising activity. The paper contributes to the field by offering new compounds that could address antibiotic resistance.
  • “Synthesis, Characterization, Computer-aided Docking Studies, and Antifungal Activity of Two-armed Quinazolin-2,4-dione Derivatives” – Journal of Molecular Structure (2024)
    This work investigates quinazolin-2,4-dione derivatives for their antifungal properties. The study includes computational docking to predict interactions with fungal targets, assisting in understanding how these compounds might exert antifungal effects. The results have implications for the development of new antifungal agents.
  • “New Quinazolin-2,4-dione Derivatives Incorporating Acylthiourea, Pyrazole and/or Oxazole Moieties as Antibacterial Agents” – RSC Advances (2024)
    This study details the synthesis of quinazolin-2,4-dione derivatives modified with acylthiourea, pyrazole, or oxazole moieties. The derivatives were evaluated for antibacterial efficacy, and the findings suggest they are potent agents against various bacterial strains. This paper is valuable in antibacterial research, especially for its exploration of structural modifications to enhance bioactivity.

Conclusion

Dr. Abdelmonsef’s achievements in organic chemistry, bioinformatics, and drug design position him as a strong candidate for the Best Researcher Award. His publication history, citation impact, and international collaborations are significant strengths, while further diversification in research topics and methodologies could enhance his candidacy further. Overall, he demonstrates considerable expertise and dedication, making him a worthy nominee for this prestigious award.

 

Adalberto Santos | Genetic Humana | Best Researcher Award

Dr . Adalberto Santos | Genetic Humana | Best Researcher Award 

Doctor , Fiocruz , Brazil

Dr. Adalberto Rezende Santos is a leading researcher in Cellular and Molecular Biology with a distinguished career at the Oswaldo Cruz Foundation (Fiocruz). Since earning his Ph.D. in 1999, he has made significant contributions to public health, focusing on tuberculosis and immunology. Dr. Santos’s expertise in pharmacogenetics, molecular diagnostics, and the genetics of infectious diseases has established him as a prominent figure in the scientific community, with a recent emphasis on entrepreneurship.

Profile

ORCiD

Strengths for the Award

  1. Extensive Research Experience: Dr. Adalberto Rezende Santos has a distinguished career in Cellular and Molecular Biology with over two decades of research experience, primarily focusing on infectious diseases such as tuberculosis and leprosy. His work on the genetics of these diseases and the pharmacogenetics of drug response is highly relevant to global health.
  2. Significant Research Contributions: Dr. Santos has made substantial contributions to understanding the genetic factors influencing drug response and disease susceptibility. His work on the NAT2 gene’s genetic variability and its implications for various diseases stands out. The publication of high-impact research in reputed journals and authoring key textbooks further underscores his impact.
  3. Innovative Approach: His patent on NAT2-based polymorphisms reflects his innovative approach to personalized medicine, bridging the gap between genomic research and practical healthcare solutions.
  4. Leadership and Collaboration: Dr. Santos has held prominent positions, such as the Head of the Tuberculosis Research Laboratory at the Federal University of Rio de Janeiro. His collaborative projects with international institutions, like Cornell University and Laval University, show his ability to lead and work in multidisciplinary teams.
  5. Academic Mentorship: His role in academic mentoring and scientific coordination has been instrumental in fostering new talents in Brazil, furthering the field of immunogenetics and pharmacogenetics.

Areas for Improvement 

  1. Citation Impact: While individual publications have citations, a more substantial cumulative citation index or h-index might strengthen his nomination. Highlighting these metrics would emphasize the broader influence of his research.
  2. Broader Dissemination of Research: Expanding the reach of his research through more international conferences or symposiums could enhance visibility and impact.
  3. Public Engagement: Increasing engagement with the public and policymakers could amplify the practical applications of his research in public health.

    Education

    Dr. Santos earned his Ph.D. in Cellular and Molecular Biology from the Oswaldo Cruz Foundation in 1999. His academic journey has been marked by a deep commitment to understanding the genetic factors influencing infectious diseases, shaping his innovative approaches to public health.

     Experience

    Dr. Santos has over two decades of experience as a Senior Researcher at the Oswaldo Cruz Foundation. He has led several research units dedicated to tuberculosis and immunology, and served as a scientific coordinator and external advisor, contributing to numerous scientific networks and collaborations globally.

    Research Interests

    Dr. Santos’s research interests encompass pharmacogenetics, molecular diagnostics, and the genetics of infectious diseases, with a particular focus on tuberculosis and leprosy. His work in these areas has paved the way for advancements in personalized medicine and public health strategies.

     Awards

    Dr. Santos has been recognized for his groundbreaking work in pharmacogenetics and molecular diagnostics. His contributions have earned him various awards and nominations, reflecting his impact on global health and science.

    Publications

    Dr. Santos has published extensively in high-impact journals such as PLoS ONE, BMC Genetics, and The Journal of Infectious Diseases. His notable publications include:

    1. Pharmacogenomics and Pharmacogenetics in Drug TherapyInTech, 2021, ISBN: 9781837685271
    2. Tuberculosis – Current Issues in Diagnosis and ManagementInTech, 2015, ISBN: 9789535110491
    3. International Textbook of LeprosyAmerican Leprosy Missions, 2020

      Conclusion

      Dr. Adalberto Rezende Santos is a highly suitable candidate for the Best Researcher Award, given his extensive contributions to infectious disease research, particularly in the genetics of tuberculosis and leprosy. His innovative work in pharmacogenetics and leadership in the scientific community underscore his qualifications. Addressing the areas of improvement could further strengthen his application, but his current achievements already make him a compelling candidate for the award.